Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Genomic Biomarker Market
5.1. COVID-19 Landscape: Genomic Biomarker Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Genomic Biomarker Market, By Type
8.1. Genomic Biomarker Market, by Type, 2023-2032
8.1.1 Predictive Biomarkers
8.1.1.1. Market Revenue and Forecast (2021-2032)
8.1.2. Prognostic Biomarkers
8.1.2.1. Market Revenue and Forecast (2021-2032)
Chapter 9. Global Genomic Biomarker Market, By Disease Indication
9.1. Genomic Biomarker Market, by Disease Indication, 2023-2032
9.1.1. Oncology
9.1.1.1. Market Revenue and Forecast (2021-2032)
9.1.2. Cardiovascular Diseases
9.1.2.1. Market Revenue and Forecast (2021-2032)
9.1.3. Neurological Diseases
9.1.3.1. Market Revenue and Forecast (2021-2032)
9.1.4. Renal Disorders
9.1.4.1. Market Revenue and Forecast (2021-2032)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2021-2032)
Chapter 10. Global Genomic Biomarker Market, By End-User
10.1. Genomic Biomarker Market, by End-User, 2023-2032
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2021-2032)
10.1.2. Diagnostic Centers
10.1.2.1. Market Revenue and Forecast (2021-2032)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2021-2032)
Chapter 11. Global Genomic Biomarker Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Type (2021-2032)
11.1.2. Market Revenue and Forecast, by Disease Indication (2021-2032)
11.1.3. Market Revenue and Forecast, by End-User (2021-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Type (2021-2032)
11.1.4.2. Market Revenue and Forecast, by Disease Indication (2021-2032)
11.1.4.3. Market Revenue and Forecast, by End-User (2021-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Type (2021-2032)
11.1.5.2. Market Revenue and Forecast, by Disease Indication (2021-2032)
11.1.5.3. Market Revenue and Forecast, by End-User (2021-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Type (2021-2032)
11.2.2. Market Revenue and Forecast, by Disease Indication (2021-2032)
11.2.3. Market Revenue and Forecast, by End-User (2021-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Type (2021-2032)
11.2.4.2. Market Revenue and Forecast, by Disease Indication (2021-2032)
11.2.4.3. Market Revenue and Forecast, by End-User (2021-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Type (2021-2032)
11.2.5.2. Market Revenue and Forecast, by Disease Indication (2021-2032)
11.2.5.3. Market Revenue and Forecast, by End-User (2021-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Type (2021-2032)
11.2.6.2. Market Revenue and Forecast, by Disease Indication (2021-2032)
11.2.6.3. Market Revenue and Forecast, by End-User (2021-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Type (2021-2032)
11.2.7.2. Market Revenue and Forecast, by Disease Indication (2021-2032)
11.2.7.3. Market Revenue and Forecast, by End-User (2021-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Type (2021-2032)
11.3.2. Market Revenue and Forecast, by Disease Indication (2021-2032)
11.3.3. Market Revenue and Forecast, by End-User (2021-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Type (2021-2032)
11.3.4.2. Market Revenue and Forecast, by Disease Indication (2021-2032)
11.3.4.3. Market Revenue and Forecast, by End-User (2021-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Type (2021-2032)
11.3.5.2. Market Revenue and Forecast, by Disease Indication (2021-2032)
11.3.5.3. Market Revenue and Forecast, by End-User (2021-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Type (2021-2032)
11.3.6.2. Market Revenue and Forecast, by Disease Indication (2021-2032)
11.3.6.3. Market Revenue and Forecast, by End-User (2021-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Type (2021-2032)
11.3.7.2. Market Revenue and Forecast, by Disease Indication (2021-2032)
11.3.7.3. Market Revenue and Forecast, by End-User (2021-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Type (2021-2032)
11.4.2. Market Revenue and Forecast, by Disease Indication (2021-2032)
11.4.3. Market Revenue and Forecast, by End-User (2021-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Type (2021-2032)
11.4.4.2. Market Revenue and Forecast, by Disease Indication (2021-2032)
11.4.4.3. Market Revenue and Forecast, by End-User (2021-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Type (2021-2032)
11.4.5.2. Market Revenue and Forecast, by Disease Indication (2021-2032)
11.4.5.3. Market Revenue and Forecast, by End-User (2021-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Type (2021-2032)
11.4.6.2. Market Revenue and Forecast, by Disease Indication (2021-2032)
11.4.6.3. Market Revenue and Forecast, by End-User (2021-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Type (2021-2032)
11.4.7.2. Market Revenue and Forecast, by Disease Indication (2021-2032)
11.4.7.3. Market Revenue and Forecast, by End-User (2021-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Type (2021-2032)
11.5.2. Market Revenue and Forecast, by Disease Indication (2021-2032)
11.5.3. Market Revenue and Forecast, by End-User (2021-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Type (2021-2032)
11.5.4.2. Market Revenue and Forecast, by Disease Indication (2021-2032)
11.5.4.3. Market Revenue and Forecast, by End-User (2021-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Type (2021-2032)
11.5.5.2. Market Revenue and Forecast, by Disease Indication (2021-2032)
11.5.5.3. Market Revenue and Forecast, by End-User (2021-2032)
Chapter 12. Company Profiles
12.1. Almac Group
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Cancer Genetics Inc
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Eurofins Scientific
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Thermo Fisher Scientific Inc
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Aepodia SA
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Epigenomics AG
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. US Biomarkers Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Roche Diagnostics
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Myriad Genetics
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Bio-Rad Laboratories
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client